Company
Samsung Bioepis CO LTD
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
10
10 still marketed
Novel approvals
0
Approvals since 2021
17
Originals and new uses
Phase 3 trials
11
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Epysqli approved Nov 28, 2025
- Denosumab-Dssb approved Oct 29, 2025
- Pyzchiva approved Apr 30, 2025
- Pyzchiva approved Apr 30, 2025
- Denosumab-Dssb approved Feb 13, 2025
- Epysqli approved Jul 19, 2024
- Pyzchiva approved Jun 28, 2024
- Pyzchiva approved Jun 28, 2024
- Opuviz approved May 20, 2024
- Eticovo new use May 3, 2024
Drugs in development (1)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- SB27Phase 31 trial
Samsung Bioepis Co., Ltd. · Non-small Cell Lung Cancer Stage IV
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (10)
Newest FDA action first.
- Byooviz Ranibizumab-Nuna · 2021
- Epysqli Eculizumab-Aagh · 2024
- Hadlima Adalimumab-Bwwd · 2019
- Ontruzant Trastuzumab-Dttb · 2019
- Opuviz Aflibercept-Yszy · 2024
- Eticovo Etanercept-Ykro · 2019
- Pyzchiva Ustekinumab-Ttwe · 2024
- Pyzchiva Ustekinumab-Ttwe · 2025
- Denosumab-Dssb Denosumab-Dssb · 2025
- Renflexis Infliximab-Abda · 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.